BioP2P Staff
21st.BIO said it is granting access to its precision fermentation technology platform to ingredient manufacturers enabling the production of dairy proteins at competitive cost.
The announcement follows 21st.BIO’s successful scaling of the beta-lactoglobulin protein, a major protein in milk that provides highly valuable nutrition and textural components of milk and other dairy ingredients.
The 21st.BIO platform provides a sustainable and less carbon and resource intensive alternative to traditional animal-based production methods and helps to stabilize global food supply chains. According to recent studies, producing proteins via precision fermentation reduces greenhouse gases emissions, and land and water use by 90 to 96 percent, compared to animal-derived production.
The company said its customers have access to world-leading industrial production strains, fermentation processes, as well as support with scale-up, tech transfers to contract manufacturers, and regulatory approvals to get to market at speed and with lower costs. The technology foundation is licensed from Novozymes, who has 40 years’ experience perfecting production strains and processes for industrial production. The technology base is already used to provide dozens of food-grade products on the market today.
“We believe this is the best way for technology to support and accelerate the transition to more sustainable and better nutrition globally,” said Thomas Schmidt, CEO of 21st.BIO
Read the full release here.